Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets
Abstract
Obesity and heart failure with preserved ejection fraction (HFpEF) represent two intermingling epidemics driving perhaps the greatest unmet health problem in cardiovascular medicine in the 21st century. Many patients with HFpEF are either overweight or obese, and recent data have shown that increased body fat and its attendant metabolic sequelae have widespread, protean effects systemically and on the cardiovascular system leading to symptomatic HFpEF. The paucity of effective therapies in HFpEF underscores the importance of understanding the distinct pathophysiological mechanisms of obese HFpEF to develop novel therapies. In this review, we summarize the current understanding of the cardiovascular and non-cardiovascular features of the obese phenotype of HFpEF, how increased adiposity might pathophysiologically contribute to the phenotype, and how these processes might be targeted therapeutically.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 26, 2022
- Source ID
- 10.1093/cvr/cvac120
Entities
People
- Barry A Borlaug
- Carolyn S P Lam
- Dalane W. Kitzman
- Masaru Obokata
- Michael D Jensen
- Oliver J Rider
Organizations
- British Heart Foundation
- Gunma University
- Mayo Clinic
- National Institutes of Health
- United States Department of Defense
- University of Oxford
- Wake Forest School of Medicine